Next-Line Protocol
Treatment of Wilms Tumor in Children With Hemihyperplasia or Beckwith-Wiedemann Syndrome After VAD Neoadjuvant Therapy Fails to Achieve Resectability
This protocol covers the next therapeutic step for children who have a metastatic unilateral renal tumor of favorable histology (Wilms tumor) in the setting of a genetic predisposing condition — such as hemihyperplasia or Beckwith-Wiedemann syndrome — and whose tumor did not become resectable or did not achieve the required response during initial neoadjuvant treatment.
Clinical Scenario
The patient is a child with a metastatic unilateral renal tumor of favorable histology and a documented genetic predisposition — hemihyperplasia or Beckwith-Wiedemann syndrome. The tumor has metastasized, and a predisposing condition shapes both the initial and subsequent treatment pathway.
Prior Treatment & Failure Condition
These patients previously received the VAD regimen (vincristine, dactinomycin, doxorubicin) as neoadjuvant therapy. The intended goals of that initial line were a complete or partial tumor response at 6 weeks and surgical resectability. When those goals are not reached, this protocol defines the next step.
Next-Step Treatment Approach
The subsequent approach involves adjuvant chemotherapy tailored to tumor histology and treatment response, with the specific regimen differing based on the histologic findings. Radiation therapy is also incorporated for certain sites of disease in eligible patients.
Full regimen details, sequencing, dose considerations, and radiation criteria are available in the structured protocol below.
References
DOI: 10.6004/jnccn.2021.0037
- Neoadjuvant therapy with the VAD regimen is recommended for children with a predisposing condition and a unilateral renal tumor that has metastasized.
- Switching to regimen DD4A is recommended for patients without blastemal predominant histology or those with a complete response at 6 weeks.
- Augmented therapy with regimen I is recommended for patients with blastemal predominant histology because they are at greater risk.
- Whole lung irradiation is administered in patients with lung metastases, and extrapulmonary metastatic sites may also require radiation.
View source ↗